Date:11/3/2010

orm 10-Q, or other current reports, as filed with the Securities and Exchange Commission.For further information:Christopher TaylorHeartWare International, Inc.Email: ctaylor@heartwareinc.comPhone: +1 508 739 0864- Tables to Follow-HEARTWARE INTERNATIONAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands except share and per share data)(unaudited)Three Months Ended September 30, Nine Months Ended September 30, 2010200920102009Revenues, net$
3,817$
7,507$
34,277$
,952Cost of revenues6,0034,10415,9766,401Gross profit7,8143,40318,3015,551Operating expenses:Selling, general and administrative6,9933,14919,23811,721Research and development9,3133,64621,5809,994Total operating expenses16,3066,79540,81821,715Loss from operations(8,492)(3,392)(22,517)(16,164)Other income (expense), net648(2,482)147(2,834)Net loss$
(7,844)$
(5,874)$  (22,370)$   (18,998)Net loss per common share - basic and diluted$
(0.57)$
(0.60)$
(1.66)$
(2.07)Weighted average shares outstanding - basic and diluted13,752,8299,715,57713,467,5409,156,074HEARTWARE INTERNATIONAL, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)

(unaudited)September 30,
2010December 31,
2009ASSETSCurrent assets:Cash and cash equivalents $
7,498$
50,835Short-term investments, net21,495--Accounts receivable, net8,29011,385Inventories, net17,2198,871Prepaid expenses and other current assets2,2651,663Total current assets116,76772,754Property, plant and equipment, net6,8423,719Other intangible assets, net1,4861,192Long-term investments, net4,008—Restricted cash288288Total assets$
29,391$
77,953LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
3,143$
3,122Accrued expenses and other current liabilities7,0893,848Total current liabilities10,2326,970Commitments and contingenciesStockholders' equity119,15970,983Total liabilities and stockholders' equ
'/>"/>

SOURCE HeartWare International, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. HeartWare to Report Financial Results for Third Quarter of 2010
2. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
3. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
4. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
5. HeartWare International Reports Third Quarter Revenues of $7.5 Million
6. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
7. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
8. Presentation of HeartWare Clinical Results
9. Saudi Arabias King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy
10. International Isotopes Inc. Announces Completion of a $5.8 Million Private Placement
11. Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited